You just read:

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

News provided by

Sanofi

Feb 06, 2019, 11:53 ET